GlassScriptPhysician profile
Erin B Hemsell
NPI 1104051895
$2,670.01
in general payments reported to CMS, 2019-2025
24 companies · $469 in 2025
The $469 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $145 · 2021: $252 · 2022: $464 · 2023: $784 · 2024: $372 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.85 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $564.72 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $518.70 | 2019-2023 | |
| Avion Pharmaceuticals | $197.40 | 2019-2023 | Balcoltra |
| Pfizer INC. | $193.16 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $142.60 | 2023-2024 | Myfembree |
| Exeltis, USA INC. | $140.28 | 2020-2024 | Slynd |
| Intuitive Surgical, INC. | $124.08 | 2022 | |
| Mayne Pharma Commercial LLC | $112.36 | 2021-2025 | |
| Coopersurgical, INC. | $107.92 | 2021-2025 | Ally II Ups, Endosee |
| Biogen, INC. | $105.29 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $84.93 | 2020-2024 | Aptima |
| Amgen INC. | $60.42 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $48.32 | 2024 | Exparel, Zilretta, Iovera |
| Millicent US INC | $31.57 | 2020-2024 | Intrarosa, Femring |
| Merck Sharp & Dohme LLC | $30.65 | 2019-2024 | Gardasil 9, Gardasil |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.59 | 2022 | |
| Therapeuticsmd, INC. | $28.63 | 2021-2022 | |
| Becton, Dickinson and Company | $28.27 | 2024 | Bd Max System, Bd Max Instrument |
| Organon LLC | $27.28 | 2023 | Nexplanon |
| Biom'Up France Sas | $24.64 | 2020 | |
| Daiichi Sankyo INC. | $21.51 | 2022 | |
| Sage Therapeutics, LLC | $19.30 | 2024 | |
| Myovant Sciences INC. | $14.38 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Hemsell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.